长春高新技术产业（集团）股份有限公司第十一届董事会第十三次会议决议公告

Group 1 - The company held its 13th meeting of the 11th Board of Directors on September 17, 2025, with all 9 directors participating in the voting [2][4][5] - The meeting approved a proposal for a collaboration between the subsidiary, Changchun Jinsai Pharmaceutical Co., Ltd., and Denmark's ALK-Abelló A/S for the development and commercialization of allergen-specific immunotherapy (AIT) products in China [7][8][11] Group 2 - The collaboration includes exclusive rights for three products developed by ALK in mainland China, which are a subcutaneous injection for house dust mite allergens, a sublingual tablet for allergic asthma and rhinitis, and a skin prick test kit for mite allergens [12][14] - The agreement stipulates a total initial payment of €32.7 million, with additional milestone payments based on regulatory progress and sales performance, potentially totaling €105 million [15][16] Group 3 - ALK is a global specialty pharmaceutical company focused on allergy and asthma treatments, with a significant market share exceeding 45% in the allergen immunotherapy sector [13] - The partnership aims to leverage the growing market potential in China, where the prevalence of dust mite allergies is high but treatment penetration remains low, with less than 1 million patients currently receiving allergen-specific immunotherapy [16]